Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueGross ProfitLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Maze Therapeutics (MAZE) Leases (2024 - 2026)

Maze Therapeutics' Leases history spans 3 years, with the latest figure at $19.3 million for Q1 2026.

  • On a quarterly basis, Leases fell 14.22% to $19.3 million in Q1 2026 year-over-year; TTM through Mar 2026 was $19.3 million, a 14.22% decrease, with the full-year FY2025 number at $20.1 million, down 13.48% from a year prior.
  • Leases hit $19.3 million in Q1 2026 for Maze Therapeutics, down from $20.1 million in the prior quarter.
  • Over the last five years, Leases for MAZE hit a ceiling of $23.2 million in Q4 2024 and a floor of $19.3 million in Q1 2026.
  • Historically, Leases has averaged $21.3 million across 3 years, with a median of $21.3 million in 2025.
  • Biggest five-year swings in Leases: dropped 13.48% in 2025 and later dropped 14.22% in 2026.
  • Tracing MAZE's Leases over 3 years: stood at $23.2 million in 2024, then decreased by 13.48% to $20.1 million in 2025, then fell by 4.13% to $19.3 million in 2026.
  • Business Quant data shows Leases for MAZE at $19.3 million in Q1 2026, $20.1 million in Q4 2025, and $20.9 million in Q3 2025.